Researchers from the University of Colorado presented preclinical data for the myeloid leukemia cell differentiation protein Mcl-1 inhibitor S-64315, currently in phase I clinical development for the treatment of hematologic cancers.
Inhibition of OX40 is known to induce and maintain responses in moderate to severe atopic dermatitis (AD). Astria Therapeutics Inc. and Ichnos Sciences Inc. are developing STAR-0310, a YTE-modified (M252Y/S254T/T256E) monoclonal antibody targeting OX40.
The cannabinoid CB1 receptor inverse agonist INV-202 (monlunabant) is in clinical studies at Inversago Pharma Inc. as a potentially first-in-class drug for metabolic disorders, including diabetic kidney disease and obesity.
Cartography Biosciences Inc. announced it has entered into a multiyear, strategic collaboration agreement with Gilead Sciences Inc. to discover and develop therapies for patients with triple-negative breast cancer and adenocarcinoma.
Be Biopharma Inc. has announced the FDA’s clearance of its IND for BE-101, an autologous potentially first-in-class B-cell medicine in development for the treatment of hemophilia B.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of renal failure characterized by development of multiple fluid-filled cysts linked to increased cAMP levels and fibrosis in the kidneys leading to progressive renal failure and need for dialysis or renal transplant.
Bispecific T-cell-engaging antibodies have emerged as therapeutic options for the treatment of cancer, but limitations such as short half-life remain to be addressed. Researchers from Biontech SE reported the preclinical pharmacology and efficacy of BNT-142, a bispecific antibody targeting claudin-6 (CLDN6) and the T-cell marker CD3.
Scientists from the PsychENCODE Consortium have analyzed the brain transcriptome in a coordinated series of studies to map all the cell types, genes, epigenetic factors, and molecular pathways involved in different psychiatric disorders. After a first set of projects based on bulk analysis, the second phase of this project included 14 simultaneous publications that revealed the cellular atlas of post-traumatic stress disorder (PTSD) and major depressive disorder (MDD), among others.
Merck Sharp & Dohme LLC has described antibody-drug conjugates (ADCs) comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to exatecan through a linker reported to be useful for the treatment of cancer.
RSS
